BofA Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Raises Target Price to $118

Futu News10:32 · Ratings

Sector Update: Health Care Stocks Weaker Late Afternoon

MT Newswires04:58

J.P. Morgan Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating

Futu News01:31 · Ratings

Intra-Cellular Therapies Enters Settlement Agreement With Sandoz Resolving Patent Litigation Related To CAPLYTA Patent; No Terms Disclosed

BenzingaJan 10 20:07

Express News | Intra-Cellular Therapies Inc - Sandoz to Sell Generic Caplyta From July 1, 2040

BreakingsJan 10 19:31

Intra-Cellular Therapies Settles CAPLYTA (Lumateperone) Patent Litigation With Sandoz

GlobeNewswireJan 10 19:30